IRIS
ALFIERI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.270
AS - Asia 7.167
EU - Europa 6.837
SA - Sud America 1.134
AF - Africa 379
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 24.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.069
SG - Singapore 2.896
CN - Cina 2.482
IT - Italia 1.361
IE - Irlanda 1.105
FI - Finlandia 1.072
BR - Brasile 940
SE - Svezia 934
DE - Germania 724
HK - Hong Kong 556
UA - Ucraina 484
VN - Vietnam 424
NL - Olanda 285
TR - Turchia 271
ZA - Sudafrica 236
GB - Regno Unito 180
RU - Federazione Russa 164
IN - India 158
FR - Francia 146
CA - Canada 132
AT - Austria 95
BE - Belgio 84
AR - Argentina 82
CI - Costa d'Avorio 73
BD - Bangladesh 59
PL - Polonia 50
ID - Indonesia 46
MX - Messico 45
JP - Giappone 44
IQ - Iraq 36
ES - Italia 34
EC - Ecuador 32
CZ - Repubblica Ceca 31
KR - Corea 29
PK - Pakistan 27
CO - Colombia 22
LT - Lituania 21
MA - Marocco 21
UZ - Uzbekistan 21
IR - Iran 18
VE - Venezuela 15
TN - Tunisia 13
PY - Paraguay 12
AZ - Azerbaigian 11
KE - Kenya 11
AL - Albania 10
CL - Cile 9
JO - Giordania 9
RO - Romania 9
EG - Egitto 8
HU - Ungheria 8
PS - Palestinian Territory 8
UY - Uruguay 8
PE - Perù 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
EE - Estonia 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LB - Libano 6
LU - Lussemburgo 6
NP - Nepal 6
SA - Arabia Saudita 6
CH - Svizzera 5
JM - Giamaica 5
CR - Costa Rica 4
DZ - Algeria 4
HN - Honduras 4
IL - Israele 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
AM - Armenia 3
AO - Angola 3
AU - Australia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
LV - Lettonia 3
MD - Moldavia 3
MY - Malesia 3
PA - Panama 3
QA - Qatar 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
CY - Cipro 2
EU - Europa 2
LK - Sri Lanka 2
OM - Oman 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
TW - Taiwan 2
AD - Andorra 1
BY - Bielorussia 1
CG - Congo 1
Totale 24.783
Salva come PNG Salva come JPEG
Città #
Singapore 1.461
Dublin 1.103
Chandler 1.038
Ashburn 965
Dallas 940
Beijing 635
Santa Clara 629
Jacksonville 560
Hong Kong 549
Ann Arbor 508
Parma 462
Dearborn 397
Boardman 346
Nanjing 251
Izmir 233
New York 228
Johannesburg 227
Shanghai 226
Munich 197
Princeton 196
Los Angeles 186
San Mateo 169
Ho Chi Minh City 159
Hefei 141
Bremen 135
Wilmington 115
Helsinki 106
Milan 98
Nanchang 92
São Paulo 89
Kunming 88
Chicago 87
Hanoi 84
Moscow 83
Shenyang 82
Vienna 78
Jinan 75
Hebei 74
Abidjan 73
Buffalo 72
Toronto 71
Woodbridge 68
Brussels 66
Des Moines 66
Marseille 56
Tianjin 55
Columbus 47
Seattle 47
Pune 46
Turku 46
Guangzhou 43
Jiaxing 42
Houston 41
Changsha 40
Amsterdam 39
Warsaw 39
Bologna 38
London 36
The Dalles 36
Brooklyn 35
Frankfurt am Main 34
Modena 34
Rio de Janeiro 34
Council Bluffs 33
Jakarta 32
Denver 31
Düsseldorf 30
Tokyo 30
Stockholm 29
Hangzhou 27
Seoul 27
Norwalk 26
Phoenix 24
Reggio Emilia 24
Rome 24
Brasília 23
Haiphong 23
Manchester 23
Redmond 23
Belo Horizonte 22
Leawood 22
Nuremberg 22
Montreal 21
Curitiba 20
Fremont 20
San Francisco 20
Tashkent 20
Zhengzhou 20
Campinas 19
Poplar 19
Chennai 18
Augusta 16
Boston 16
Atlanta 15
Brno 15
Dhaka 15
Wuhan 15
Ankara 14
Baghdad 14
Brescia 14
Totale 15.102
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 310
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 227
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 219
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 207
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 204
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 201
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 189
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 184
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 180
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 179
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 171
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 168
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 168
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Characterization of gefitinib uptake in NSCLC cell lines 163
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 163
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 163
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 163
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 163
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 162
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 160
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 158
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 158
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 156
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 156
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 155
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 155
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 155
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 154
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 151
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 151
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 151
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 149
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 148
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 148
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 147
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 147
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 146
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 146
Antitumoral effect of a nanotechnology-based photodynamic therapy. 146
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 144
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 144
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 144
5-benzylidene-hydantoins as new inhibitors of cell proliferation 143
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 142
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 141
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 140
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 139
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 139
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 139
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 136
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 136
Attenuata induzione del gene SNAT-2 in fibroblasti umani senescenti esposti a stress iperosmolare 135
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 135
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 135
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 134
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 134
An original application of plasma expanders: heart-lung preservation. 134
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 133
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 133
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 132
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 132
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 131
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 131
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 131
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 130
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 129
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 129
New MDR1 inhibitors for overcoming multidrug resistance 129
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 128
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 128
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 128
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 128
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 128
SiO2/SiC core-shell nanowires for nanomedicine applications 128
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 127
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 126
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 124
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 123
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 123
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 123
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 122
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 122
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 122
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 122
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 121
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 121
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 121
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 121
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 121
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 119
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 119
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 118
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 117
SiO2/SiC core-shell nanowires for nanomedicine applications 117
Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells 116
Different HSP70 expression and cell survival during adaptive responses of 3T3 and transformed 3T3 to osmotic stress 115
Totale 14.609
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.558
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.558
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021846 0 0 0 0 0 24 128 53 244 49 287 61
2021/20221.011 44 22 52 65 34 14 135 119 60 71 67 328
2022/20234.206 399 434 276 278 414 466 44 297 1.364 25 169 40
2023/20241.762 86 139 60 64 157 403 129 131 68 88 155 282
2024/20255.391 177 281 345 406 496 566 305 223 737 463 472 920
2025/20266.392 1.026 1.078 1.418 1.061 1.562 247 0 0 0 0 0 0
Totale 25.131